

Adult CIRB - Late Phase Emphasis Meeting Agenda

June 16, 2022

I Continuing Review

EA2197, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial (Protocol Version Date 03/03/22)

II Continuing Review

EA5181, Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (Protocol Version Date 12/18/20)

III New Study - Initial Review

ABTC-1604, Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters (Protocol Version Date 05/04/22)

IV New Study - Initial Review

CCTG-HN11, SPECT-CT Guided Elective Contralateral Neck Treatment (Select) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial (Protocol Version Date 05/06/22)

V New Study - Initial Review

S2200, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2) (Protocol Version Date 05/02/22)

VI Amendment

A071701, Genomically-Guided Treatment Trial in Brain Metastases (Protocol Version Date 05/17/22)

VII Amendment

NRG-BN003, Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma (Protocol Version Date 05/13/22)
